CROs and Preclinical Development

Contributed by:

Denise Myshko

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

To create efficiency and offload the need to maintain staff, instruments, and consumables for irregularly scheduled projects and projects that extend beyond their scope, more labs are engaging CROs as outsourcing partners, according to a recent report by BioInformatics LLC. Thomas Jones, Ph.D., senior director, toxicology and pathology, Eli Lilly and Company, believes it is likely that more and more of the preclinical studies conducted each year to support drug discovery and development will be managed by CROs. “With this shift, CROs must accept greater responsibility in terms of product delivery,” he says. “In addition to running studies and supplying data, they must emerge as the true experts in the study types and models… Experts on this topics Thomas Jones, Ph.D., Senior Director, Toxicology and Pathology, Eli Lilly and Company Peter Smith, Ph.D., Senior VP, Nonclinical Development Sciences at Millennium Pharmaceuticals Inc.: The Takeda Oncology Company Alain Stricker-Krongrad, Ph.D., Chief Scientific Officer at Charles River

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK